Delivery Order SPE2DB20D3505-SPE2DB25FYBTA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $30,929.96 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical supply will be...
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $34,670.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract leveraging AmerisourceBergen's established pharmaceutical distribution capabilities. The contract is executed under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $7,945.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with a completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $18,297.80 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $5,128.38. This firm fixed-price, non-set-aside contract is classified as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $9,481.08 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,877.08 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen medications on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a $66,460.68 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and carries an ultimate completion date of August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this delivery order, with performance taking place at the company's Conshohocken...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FYBTADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $22.8K to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 18, 2025, with completion scheduled for August 19, 2025. This non-set-aside contract employs firm fixed pricing and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle through December 2026. The product will be delivered to the company's Conshohocken, Pennsylvania headquarters, where the firm maintains its corporate office and primary operations as a major pharmaceutical distributor serving federal healthcare systems. AmerisourceBergen Drug Corp is a critical vendor within the Defense Health Agency's pharmaceutical supply chain, delivering brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support military healthcare programs worldwide. This delivery order for Dupixent, a specialty biologic medication, exemplifies the company's role in supplying specialized pharmaceutical products to meet federal medical procurement requirements. The firm's consistent receipt of competitively awarded contracts through DLA demonstrates its capability to fulfill complex pharmaceutical supply needs for the military healthcare system and other federal agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.8k | 8/18/25 |